May 14, 2018
TissueTech, Inc. Awarded Patent for Compositions of Morselized Umbilical Cord and Amniotic Membrane
MIAMI – May 14, 2018 – TissueTech Inc., the pioneer in the development and clinical application of regenerative amniotic tissue-based products, announced that it has been awarded patent 9,808,491 by the U.S. Patent Trademark Office. The patent applies to the use of a gel composition comprising morselized placental amniotic membrane and/or morselized umbilical cord. as a method for treating an ocular wound or repairing damaged ocular tissue. “TissueTech has been the leader in the development and clinical application of amniotic membrane transplantation for the treatment of a variety of patient conditions in ophthalmology, chronic wound care, orthopedics and sports medicine,” said Amy Tseng, Chief Executive Officer of TissueTech. “We are excited that this patent represents our continued innovation and is another step forward in excelling our technological advances in the industry.” TissueTech’s subsidiary BioTissue, Inc. is the market leader in the clinical application of amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface. BioTissue markets the only such technology that has been recognized by the Food and Drug Administration for optimizing wound healing while suppressing inflammation and scarring. Numerous disease states are the direct result of damage to normal tissue and the associated inflammation, along with the body’s consequent inability to restore a normal state of function. It is known that regenerative healing occurs in the fetal environment due to the inherent ability of the placental tissues to modulate inflammation and create an environment that is conducive to healing. Research has shown that this occurs because the placental tissues, particularly the umbilical cord and amniotic membrane, have innate regenerative properties. More importantly, these properties can be preserved and transplanted to other environments. TissueTech’s proprietary CryoTek® preservation process is the only process that has been proven to produce an allograft that is structurally and biologically equivalent to fresh tissue.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical Inc. and BioTissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical markets products for use in the musculoskeletal and wound care markets; BioTissue markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform.